294 results on '"Glucagon-Like Peptide 1 adverse effects"'
Search Results
2. Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.
- Author
-
Ituarte BE, Taylor MA, Thomas SI, Sharma D, High R, Wysong A, and Wei EX
- Subjects
- Humans, United States epidemiology, Cross-Sectional Studies, Male, Female, Middle Aged, Adverse Drug Reaction Reporting Systems statistics & numerical data, Hypoglycemic Agents adverse effects, Hypoglycemic Agents administration & dosage, Glucagon-Like Peptide 1 agonists, Glucagon-Like Peptide 1 adverse effects, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide-1 Receptor agonists, Aged, Liraglutide adverse effects, Liraglutide therapeutic use, Exenatide adverse effects, Exenatide administration & dosage, Adult, Drug Eruptions etiology, Drug Eruptions epidemiology, United States Food and Drug Administration
- Published
- 2024
3. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.
- Author
-
Salazar CE, Patil MK, Aihie O, Cruz N, and Nambudiri VE
- Subjects
- Humans, Skin pathology, Skin drug effects, Liraglutide adverse effects, Liraglutide therapeutic use, Glucagon-Like Peptide-1 Receptor agonists, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 agonists, Hypoglycemic Agents adverse effects, Drug Eruptions etiology, Drug Eruptions diagnosis, Drug Eruptions pathology
- Abstract
Glucagon-like-peptide-1 (GLP-1) agonists are an emerging class of medications used to manage type 2 diabetes mellitus (T2DM) and weight loss, with demonstrated efficacy in reducing hemoglobin A1c levels, body mass index, and adverse cardiovascular events. While previous studies have reviewed notable cutaneous adverse effects with other antidiabetic medications, little is known about GLP-1 agonist-induced cutaneous reactions. Nevertheless, rare but significant cutaneous adverse reactions have been reported, including but not limited to dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions. As GLP-1 induced cutaneous reactions are diverse, diagnosis requires clinical suspicion, thorough history-taking, and supportive histopathological findings when available. Management involves cessation of the offending agent with a tailored regimen to address inflammatory and/or immunogenic etiologies as well as irritative symptoms. This review aims to consolidate available information from case reports and case series regarding rare skin-related adverse outcomes due to GLP-1 use, aiming to provide a comprehensive overview of the presentation, pathogenesis, and management for dermatologists and other clinicians., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
- Author
-
Gilbert MP, Skelly J, Hernandez AF, Green JB, Krychtiuk KA, Granger CB, Leiter LA, McMurray JJV, Del Prato S, and Pratley RE
- Subjects
- Humans, Aged, Hypoglycemic Agents adverse effects, Treatment Outcome, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 chemically induced, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Cardiovascular Diseases etiology, Glucagon-Like Peptide 1 analogs & derivatives
- Abstract
Aim: To analyse the effects of albiglutide, a glucagon-like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515)., Materials and Methods: We conducted a post hoc analysis of the primary endpoint of the Harmony Outcomes trial-time to first occurrence of a major adverse cardiovascular event-in subgroups of participants aged <65 and ≥65 years and <75 and ≥75 years at baseline. Hazard ratios and 95% confidence intervals (CIs) were generated using Cox proportional hazards regression., Results: The analysis population included 9462 Harmony Outcomes participants, including 4748 patients ≥65 and 1140 patients ≥75 years at baseline. Hazard ratios for the prevention of major adverse cardiovascular events were 0.66 (95% CI, 0.53-0.82) in persons <65 and 0.86 (95% CI, 0.71-1.04) in those ≥65 years (age interaction p = .07), and 0.78 (95% CI, 0.67-0.91) in <75 and 0.70 (95% CI, 0.48-1.01) in ≥75 year age groups (interaction p = .6). When analysed as a continuous variable, age did not modify the effect of albiglutide on the primary endpoint., Conclusions: This post hoc analysis adds to the body of literature showing that glucagon-like peptide 1 receptor agonists added to standard type 2 diabetes therapy safely reduce the incidence of cardiovascular events in older adults with established cardiovascular disease. In this analysis, the risk-benefit profile was similar between younger and older age groups treated with albiglutide., (© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
- Author
-
Chen W, Cai P, Zou W, and Fu Z
- Subjects
- Male, Humans, Female, Middle Aged, Aged, Pharmacovigilance, Databases, Factual, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor Agonists, Binge-Eating Disorder
- Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used due to their profound efficacy in glycemic control and weight management. Within real-world contexts, the manifestation of certain psychiatric adverse events (AEs) has been observed, which is potentially linked to the administration of GLP-1 RAs. The objective of this study was to undertake a comprehensive investigation and characterization of the psychiatric AEs associated with GLP-1 RAs., Methods: We retrieved reports of AEs associated with treatment with GLP-1 RAs during the period from the first quarter (Q1) of 2004 to Q1 2023 from the FDA Adverse Event Reporting System (FAERS) database. Descriptive analysis was performed to examine the clinical characteristics and time to onset of the psychiatric AEs caused by GLP-1 RAs. Moreover, disproportionality analyses were performed using the reporting odds ratio (ROR) to identify GLP-1 RA-related psychiatric AEs., Results: A total of 8,240 reports of psychiatric AEs were analyzed out of 181,238 AE reports with treatment with GLP-1 RAs. Among these cases, a higher percentage was represented by women compared to men (65.89% vs . 30.96%). The median age of these patients was 56 years, with an interquartile range (IQR) of 48-67 years, based on data available in 286 case reports. This study showed that the median time to onset of the overall GLP-1 RA-related AEs was 31 days (IQR = 7-145.4 days), which varied among GLP-1 RA regimens. Specifically, exenatide had a significantly longer onset time at 45 days (IQR = 11-213 days), with statistically significant differences from the onset times of the other five GLP-1 RAs ( p < 0.0001). Moreover, eight categories of psychiatric AEs, namely, nervousness (ROR = 1.97, 95% CI = 1.85-2.11), stress (ROR = 1.28, 95% CI = 1.19-1.38), eating disorder (ROR = 1.57, 95% CI = 1.40-1.77), fear of injection (ROR = 1.96, 95% CI = 1.60-2.40), sleep disorder due to general medical condition-insomnia type (ROR = 2.01, 95% CI = 1.60-2.52), binge eating (ROR = 2.70, 95% CI = 1.75-4.16), fear of eating (ROR 3.35, 95% CI = 1.65-6.78), and self-induced vomiting (ROR = 3.77, 95% CI = 1.77-8.03), were defined as GLP-1 RA-related psychiatric AEs through disproportionality analysis., Conclusion: Our findings demonstrate a significant association between GLP-1 RAs and the development of specific psychiatric AEs. Despite the observational nature of this pharmacovigilance study and the inherent limitations of the FAERS database, our preliminary findings in this work could provide a better basis for understanding the potential psychiatric AEs that may occur with GLP-1 RA treatment, assisting clinicians to focus on these AEs and provide early intervention for optimal risk management., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Chen, Cai, Zou and Fu.)
- Published
- 2024
- Full Text
- View/download PDF
6. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
- Author
-
Ansari HUH, Qazi SU, Sajid F, Altaf Z, Ghazanfar S, Naveed N, Ashfaq AS, Siddiqui AH, Iqbal H, and Qazi S
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1 adverse effects, Obesity drug therapy, Obesity complications, Weight Loss, Lipids, Triglycerides, Lipoproteins, HDL, Lipoproteins, LDL, Cholesterol, Glucagon-Like Peptide-1 Receptor agonists, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 complications, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control
- Abstract
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes mellitus, show promise in promoting weight loss and improving heart health in obese individuals without diabetes. Our goal was to examine existing research for conclusive evidence on various types of GLP-1 RAs for weight loss and cardiometabolic benefits in obesity without diabetes., Methods: We conducted an electronic search on PubMed, Scopus, and Cochrane Central using keywords, such as "GLP-1 RA," "obesity," and "weight loss." We considered all available global GLP-1 RAs for inclusion. Our analysis focused on weight loss, blood pressure (BP) changes (systolic and diastolic BPs), and lipid profile effects (high-density lipoprotein, low-density lipoprotein, total cholesterol, and triacylglycerol). We used a random-effects meta-analysis with the standardized mean difference (SMD), mean difference (MD), odds ratio, and relative risk to present the results., Results: Our search yielded a total of 7535 articles. We included 15 trials in our study. GLP-1 RAs led to significant weight loss (MD, -8.77 kg; P <.01) in obese individuals. GLP-1 RAs also improved the systolic BP (MD, -4.13 mm Hg; P <.01), diastolic BP (MD, -1.39 mm Hg; P <.01), and lipid profiles, including improved levels of triacylglycerol (SMD, -0.99 mg/dL; P <.01), total cholesterol (SMD, -0.73 mg/dL; P <.01), very low-density lipoprotein (SMD, -1.11 mg/dL; P <.01), and low-density lipoprotein (SMD, -0.27 mg/dL; P <.01), and significantly increased high-density lipoprotein levels (SMD, 0.11 mg/dL; P <.01). However, GLP-1 RAs were associated with an increased risk of gastrointestinal adverse events., Conclusion: GLP-1 RAs were found to be beneficial for not only weight loss but also reduction in risk factors for cardiovascular disease such as BP and lipid profile. Consistent beneficial results were observed across the various subtypes of GLP-1 RAs., Competing Interests: Disclosure The authors have no conflicts of interest to disclose., (Copyright © 2023 AACE. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
- Author
-
Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, and Paccou J
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Glucagon-Like Peptide-1 Receptor Agonists, Bone Density, Glucagon-Like Peptide 1 adverse effects, Obesity complications, Obesity drug therapy, Weight Loss, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptide-1 Receptor therapeutic use, Liraglutide pharmacology, Liraglutide therapeutic use, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy
- Abstract
Glucagon-like peptide-1 Receptor agonists (GLP-1Ras) such as liraglutide and semaglutide have been recently approved as medications for chronic weight management in people living with obesity (PwO); GLP-1 may enhance bone metabolism and improve bone quality. However, the effects of GLP-1Ras on skeletal health remain to be determined and that's the purpose of this narrative review. Nevertheless, bone consequences of intentional weight loss interventions in PwO are well known: (i) significant weight loss induced by caloric restriction and bariatric surgery results in accelerated bone turnover and bone loss, and (ii) unlike caloric restriction interventions, PwO experience a substantial deterioration in bone microarchitecture and strength associated with an increased risk of fracture after bariatric surgery especially malabsorptive procedures. Liraglutide seems to have a positive effect on bone material properties despite significant weight loss in several rodent models. However, most of positive effects on bone mineral density and microarchitecture were observed at concentration much higher than approved for obesity care in humans. No data have been reported in preclinical models with semaglutide. The current evidence of the effects of GLP-1Ra on bone health in PwO is limited. Indeed, studies on the use of GLP-1Ra mostly included patients with diabetes who were administered a dose used in this condition, did not have adequate bone parameters as primary endpoints, and had short follow-up periods. Further studies are needed to investigate the bone impact of GLP-1Ra, dual- and triple-receptor agonists for GLP-1, glucose-dependent insulin releasing polypeptide (GIP), and glucagon in PwO., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
8. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
- Author
-
Cai W, Zhang R, Yao Y, Wu Q, and Zhang J
- Subjects
- Humans, Body Weight, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Randomized Controlled Trials as Topic, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-2 Receptor, Insulins therapeutic use, Obesity drug therapy
- Abstract
Objective: To systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight., Methods: A search formula was written using search terms such as "tirzepatide," "overweight," and "obesity." A comprehensive search was conducted on databases such as PubMed, Cochrane Library, Embase, and Web of Science using a computer. Random controlled trial (RCT) literature was selected based on inclusion and exclusion criteria. After extracting the data, literature bias risk assessment and meta-analysis were conducted using RevMan 5.4 software. The search deadline is from the establishment of each database to May 2023., Results: A total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD = -1.71, 95% CI (-2.46, -0.95), p < 0.00001], [MD = -3.99, 95% CI (-3.69, -2.45), p < 0.00001], [MD = -4.02, 95% CI (-4.72, -3.31), p < 00.00001]. In terms of decreasing waist circumference, tirzepatide has a more significant advantage [MD = -4.08, 95% CI (-5.77, -2.39), p < 0.00001], [MD = -7.71, 95% CI (-10.17, -5.25), p < 0.00001], [MD = -9.15, 95% CI (-10.02, -8.29), p < 0.00001]. In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group [MD = -5.65, 95% CI (-7.47, -3.82), p < 0.001], [MD = -10.06, 95% CI (-12.86, -7.25), p < 0.001], [MD = -10.63, 95% CI (-12.42, -8.84), p < 0.001]. In comparison with placebo, tirzepatide had a prominent advantage in weight loss ≥20% and ≥25% [RR = 30.43, 95% CI (19.56, 47.33), p < 0.00001], [RR = 37.25, 95% CI (26.03, 53.30), p < 0.00001]. Subgroup analysis showed a dose-dependent therapeutic effect. In terms of safety, compared with the placebo and insulin groups, the incidence of gastrointestinal adverse reactions was markedly higher in the tirzepatide group, slightly higher to the GLP-1 RAs group. The hypoglycemic (<70 mg/dL) risk of tirzepatide was slightly higher to that of placebo and GLP-1 RAs, but significantly lower than that of the insulin group [RR = 0.46, 95% CI (0.36, 0.58), p < 0.001]. The incidence of other adverse events, including pancreatitis, cholecystitis, major adverse cardiovascular events-4, hypersensitivity reactions, and neoplasms did not show significant statistical differences compared to the control group ( p > 0.05)., Conclusion: Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Overall, its efficacy is significant and its safety is high., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Cai, Zhang, Yao, Wu and Zhang.)
- Published
- 2024
- Full Text
- View/download PDF
9. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
- Author
-
Liu BD, Udemba SC, Liang K, Tarabichi Y, Hill H, Fass R, and Song G
- Subjects
- Adult, Humans, Glucagon-Like Peptide-1 Receptor Agonists, Cohort Studies, Retrospective Studies, Glucagon-Like Peptide 1 adverse effects, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Gastroesophageal Reflux drug therapy, Gastroesophageal Reflux complications
- Abstract
Background: Shorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for gastro-oesophageal reflux disease (GERD) and its complications., Aim: To determine whether short-acting or long-acting GLP-1 RAs are associated with an increased risk of new GERD or GERD-related complications DESIGN: We used the TriNetX global database to identify adult patients with type 2 diabetes mellitus and generated two cohorts totalling 1 543 351 patients on (1) GLP-1 RA or (2) other second-line diabetes medication. Using propensity-score matching, Kaplan-Meier Analysis and Cox-proportional hazards ratio (HR), we analysed outcomes and separately examined outcomes in patients starting short-acting (≤1 day) and long-acting (≥5 days) GLP-1 RAs., Results: 177 666 patients were in each propensity-matched cohort. GLP-1 RA exposure was associated with an increased risk (HR 1.15; 95% CI 1.09 to 1.22) of erosive reflux disease (ERD). However, this was solely due to short-acting (HR 1.215; 95% CI 1.111 to 1.328), but not long-acting (HR 0.994; 95% CI 0.924 to 1.069) GLP-1 RA exposure. Short-acting GLP-1 RAs were also associated with increased risk of oesophageal stricture (HR 1.284; 95% CI 1.135 to 1.453), Barrett's without dysplasia (HR 1.372; 95% CI 1.217 to 1.546) and Barrett's with dysplasia (HR 1.505; 95% CI 1.164 to 1.946) whereas long-acting GLP-1 RAs were not. This association persisted in sensitivity analyses, and when individually examining the short-acting GLP-1 RAs liraglutide, lixisenatide and exenatide., Conclusion: Starting shorter-acting GLP-1 RAs is associated with increased risks of GERD and its complications., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
10. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.
- Author
-
Cooper DH, Ramachandra R, Ceban F, Di Vincenzo JD, Rhee TG, Mansur RB, Teopiz KM, Gill H, Ho R, Cao B, Lui LMW, Jawad MY, Arsenault J, Le GH, Ramachandra D, Guo Z, and McIntyre RS
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Depression drug therapy, Depression etiology, Protective Factors, Retrospective Studies, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 agonists, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 chemically induced
- Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonists are widely used for glycemic control in patients with diabetes mellitus (DM) and are primarily indicated for type 2 diabetes mellitus (T2DM). GLP-1 receptor agonists have also been shown to have neuroprotective and antidepressant properties. Replicated evidence suggests that individuals with DM are significantly more likely to develop depression. Herein, we aim to investigate whether GLP-1 receptor agonists can be used prophylactically on patients with DM to lower the risk of incident depression. We conducted a systematic search for English-language articles published on the PubMed/MEDLINE, Scopus, Embase, APA, PsycInfo, Ovid and Google Scholar databases from inception to June 6, 2022. Four retrospective observational studies were identified that evaluated the neuroprotective effects of GLP-1 receptor agonists on incident depression in patients with DM. We found mixed results with regards to lowering the risk of incident depression, with two studies demonstrating a significant reduction in risk and two studies showing no such effect. A single study found that dulaglutide may lower susceptibility to depression. Our results were limited by high interstudy heterogeneity, paucity of literature, and lack of controlled trials. While we did not find evidence of GLP-1 receptor agonists significantly lowering risk of incident depression in patients with DM, promising neuroprotective data presented in two of the included papers, specifically on dulaglutide where information is scarce, provide the impetus for further investigation. Future research should focus on better elucidating the neuroprotective potential of different classes and doses of GLP-1 receptor agonists using controlled trials., Competing Interests: Declaration of competing interest R.S.M has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC); speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie, Atai Life Sciences. R.S.M is a CEO of Braxia Scientific Corp. T.G.R was supported in part by the National Institute on Aging (NIA) through Yale School of Medicine (#T32AG019134) in the past 3 years. T.G.R has also been funded by the NIA (#R21AG070666), National Institute of Mental Health (#R21MH117438) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP) of the University of Connecticut. T.G.R serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. T.G.R has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. TGR is currently a co-editor-in-chief of Mental Health Science and has received honorarium payments from the publisher, John Wiley & Sons, Inc. R.H has received research grant support from NUS iHeathtech Other Operating Expenses (R-722-000-004-731). L.M.W.L has received personal fees from Braxia Scientific Corp and honoraria from Medscape. All other authors have no conflicts of interest to declare. K.M.T has received personal fees from Braxia Scientific Corp., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.
- Author
-
Yang XY, Yin S, Yu YF, Hu G, Hang FZ, Zhou ML, Liu P, and Jian WX
- Subjects
- Humans, Glycated Hemoglobin, Hypoglycemia, Insulin adverse effects, Clinical Trials as Topic, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 adverse effects
- Abstract
Objective: The study aims to evaluate tirzepatide's efficacy and safety in treating type 2 diabetes by meta-analysis and trial-sequential-analysis (TSA)., Materials and Methods: Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022. Revman5.3 and TSA 0.9.5.10 Beta were selected for meta-analysis and TSA., Results: Compared with placebo, the meta-analysis demonstrated that tirzepatide 15 mg reduced hemoglobin-type-A1C (HbA1c) (p<0.00001), fasting-serum-glucose (FSG) (p<0.00001), and weight (p<0.00001). Compared with insulin, tirzepatide 15 mg reduced HbA1c (p<0.00001), FSG (p<0.00007), and weight (p<0.00001). Compared with glucagon-like-peptide-1 receptor-agonist (GLP-1 RA), tirzepatide 15 mg reduced HbA1c (p=0.00004), FSG (p=0.001), and weight (p<0.00001). In safety endpoints, the meta-analysis revealed that adverse events (AEs) of placebo, insulin and GLP-1 RA were comparable to tirzepatide 15 mg. The total AEs (p=0.02) and gastrointestinal (GI) AEs (p=0.03) were higher in tirzepatide 15 mg than in the placebo, while hypoglycemia (<54 mg/dl) was comparable. The major adverse cardiovascular events-4 (MACE-4) (p=0.03) and hypoglycemia (<54 mg/dl) (p<0.00001) of tirzepatide 15 mg were lower when compared to insulin, while total AEs (p=0.03) were increased. Compared with GLP-1 RA, tirzepatide 15 mg was comparable in safety endpoints in total AEs and GI AEs, while hypoglycemia (<54 mg/dl) (p=0.04) was higher. TSA indicated that HgA1c, FSG, and weight benefits were conclusive. In safety endpoints, only MACE-4 and hypoglycemia (<54 mg/dl) of Tirzepatide 15 mg vs. Insulin were conclusive. Harbord regression of AEs suggested no evident publication bias (p=0.618)., Conclusions: Tirzepatide 15 mg reduced HbA1c and weight more effectively than placebo, insulin, and GLP-1 RA. Total AEs were higher than placebo and insulin but comparable to GLP-1 RA. Tirzepatide 15 mg is a kind of optimal strategy to treat type 2 diabetes. However, there is a need to focus on GI AEs.
- Published
- 2023
- Full Text
- View/download PDF
12. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
- Author
-
Cao M, Pan C, Tian Y, Wang L, Zhao Z, and Zhu B
- Subjects
- Humans, Exenatide adverse effects, Bayes Theorem, Pharmacovigilance, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Pancreatic Neoplasms, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 complications
- Abstract
Background: There are increasing data on the potential risk of pancreatic carcinoma associated with glucagon-like peptide 1 receptor agonists (GLP-1RAs)., Aim: The study aimed to determine whether GLP-1RAs are associated with increased detection of pancreatic carcinoma based on the FDA Adverse Events Reporting System and clarify its potential mechanisms through keyword co-occurrence analysis from literature database., Method: Disproportionality and Bayesian analyses were used for signal detection using reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM). Mortality, life-threatening events, and hospitalizations were also investigated. VOSviewer was adopted to generate visual analysis of keyword hotspots., Results: A total of 3073 pancreatic carcinoma cases were related to GLP-1RAs. Five GLP-1RAs were detected with signals for pancreatic carcinoma. Liraglutide had the strongest signal detection (ROR 54.45, 95% CI 51.21-57.90; PRR 52.52, 95% CI 49.49-55.73; IC 5.59; EBGM 48.30). The signals of exenatide (ROR 37.32, 95% CI 35.47-39.28; PRR 36.45, 95% CI 34.67-38.32; IC 5.00; EBGM 32.10) and lixisenatide (ROR 37.07, 95% CI 9.09-151.09; PRR 36.09; 95% CI 9.20-141.64; IC 5.17, EBGM 36.09) were stronger than those of semaglutide (ROR 7.43, 95% CI 5.22-10.57; PRR 7.39; 95% CI 5.20-10.50; IC 2.88, EBGM 7.38) and dulaglutide (ROR 6.47, 95% CI 5.56-7.54; PRR 6.45; 95% CI 5.54-7.51; IC 2.67, EBGM 6.38). The highest mortality rate occurred in exenatide (63.6%). Based on the bibliometric investigation, cAMP/protein-kinase, Ca
2+ channel, endoplasmic-reticulum stress, and oxidative stress are potential pathogenesis of pancreatic carcinoma resulting from GLP-1RAs., Conclusion: Based on this pharmacovigilance study, GLP-1RAs, except albiglutide, are associated with pancreatic carcinoma., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2023
- Full Text
- View/download PDF
13. Weight loss efficiency and safety of tirzepatide: A Systematic review.
- Author
-
Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, and Li Y
- Subjects
- Humans, Gastric Inhibitory Polypeptide, Insulin therapeutic use, Weight Loss, Obesity drug therapy, Obesity chemically induced, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 chemically induced
- Abstract
Objective: Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2DM) and obesity patients in this meta-analysis study., Methods: Cochrane Library, PubMed, Embase, Clinical Trials, and Web of Science were searched from inception to October 5, 2022. All randomized controlled trials (RCTs) were included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software., Results: In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively. In sub-analysis, the body weight of patients was significantly reduced in three tirzepatide doses (5 mg, 10 mg, and 15 mg) when compared with those of the placebo/GLP-1 RA/insulin. In terms of safety, the incidence of any adverse events and adverse events leading to study drug discontinuation was higher in the tirzepatide group, but the incidence of serious adverse events and hypoglycaemia was lower. Additionally, the gastrointestinal adverse events (including diarrhea, nausea, vomiting and decreased appetite) of tirzepatide were higher than those of placebo/basal insulin, but similar to GLP-1 RAs., Conclusion: In conclusion, tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
14. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
- Author
-
Trombara F, Cosentino N, Bonomi A, Ludergnani M, Poggio P, Gionti L, Baviera M, Colacioppo P, Roncaglioni MC, Leoni O, Bortolan F, Agostoni P, Genovese S, and Marenzi G
- Subjects
- Female, Humans, Middle Aged, Aged, Aged, 80 and over, Male, Hypoglycemic Agents adverse effects, Risk Factors, Glucagon-Like Peptide 1 adverse effects, Hospitals, Glucagon-Like Peptide-1 Receptor agonists, Diabetes Mellitus, Type 2 drug therapy, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Myocardial Infarction diagnosis, Myocardial Infarction drug therapy
- Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection. Whether their benefits occur also during hospitalization for acute myocardial infarction (AMI) in patients with diabetes mellitus (DM) is not known. We evaluated in-hospital outcomes of patients hospitalized with AMI according to their chronic use of GLP-1 RA and/or SGLT-2i., Methods: Using the health administrative databases of Lombardy, patients hospitalized with AMI from 2010 to 2019 were included. They were stratified according to DM status, then grouped into three cohorts using a propensity score matching: non-DM patients; DM patients treated with GLP-1 RA and/or SGLT-2i; DM patients not treated with GLP-1 RA/SGLT-2i. The primary endpoint of the study was the composite of in-hospital mortality, acute heart failure, and acute kidney injury requiring renal replacement therapy., Results: We identified 146,798 patients hospitalized with AMI (mean age 71 ± 13 years, 34% females, 47% STEMI; 26% with DM). After matching, 3,090 AMI patients (1030 in each group) were included in the analysis. Overall, the primary endpoint rate was 16% (n = 502) and progressively increased from non-DM patients to DM patients treated with and without GLP-1 RA/SGLT-2i (13%, 16%, and 20%, respectively; P < 0.0001). Compared with non-DM patients, DM patients with GLP-1 RA/SGLT-2i had a 30% higher risk of the primary endpoint, while those not treated with GLP-1 RA/SGLT-2i had a 60% higher risk (P < 0.0001)., Conclusion: Chronic therapy with GLP-1 RA and/or SGLT-2i has a favorable impact on the clinical outcome of DM patients hospitalized with AMI., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
15. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
- Author
-
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, and Faillie JL
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptide 1 adverse effects, Diabetes Mellitus, Type 2 diagnosis, Thyroid Neoplasms chemically induced, Thyroid Neoplasms epidemiology
- Abstract
Objective: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer., Research Design and Methods: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index., Results: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05)., Conclusions: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment., (© 2023 by the American Diabetes Association.)
- Published
- 2023
- Full Text
- View/download PDF
16. Safe and Appropriate Use of GLP-1 RAs in Treating Adult Patients With Type 2 Diabetes and Macrovascular Disease.
- Author
-
LaSalle J, Novak LM, and Blonde L
- Subjects
- Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Humans, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 chemically induced, Diabetes Mellitus, Type 2 drug therapy
- Abstract
Over the past decade, the type 2 diabetes (T2D) treatment landscape has evolved, allowing for more therapeutic options and the opportunity to tailor treatments to achieve patient treatment goals. In this video roundtable series, James LaSalle, DO; Lucia M. Novak, CRNP; and Lawrence Blonde, MD, MACE, FACP, discuss the mechanisms of action and clinical trial data for use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the safe and effective primary care management of individuals with T2D and macrovascular disease.
- Published
- 2022
- Full Text
- View/download PDF
17. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
- Author
-
McGuire DK, D'Alessio D, Nicholls SJ, Nissen SE, Riesmeyer JS, Pavo I, Sethuraman S, Heilmann CR, Kaiser JJ, and Weerakkody GJ
- Subjects
- Bayes Theorem, Drugs, Investigational therapeutic use, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Humans, Randomized Controlled Trials as Topic, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Treatment Outcome, Cardiovascular Diseases epidemiology, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents adverse effects
- Abstract
Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational drug does not increase CV risk. Recently, several glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter 2 inhibitors (SGLT-2i) demonstrated reduced CV risk. Consequently, future T2DM therapy trials could face new ethical and clinical challenges if CVOTs continue with the traditional, placebo-controlled design. To address this challenge, here we review the methodologic considerations in transitioning to active-controlled CVOTs and describe the statistical design of a CVOT to assess non-inferiority versus an active comparator and if non-inferiority is proven, using novel methods to assess for superiority versus an imputed placebo. Specifically, as an example of such methodology, we introduce the statistical considerations used for the design of the "Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events (MACE) in Patients with Type 2 Diabetes" trial (SURPASS CVOT). It is the first active-controlled CVOT assessing antihyperglycemic therapy in patients with T2DM designed to demonstrate CV efficacy of the investigational drug, tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 RA, by establishing non-inferiority to an active comparator with proven CV efficacy, dulaglutide. To determine the efficacy margin for the hazard ratio, tirzepatide versus dulaglutide, for the composite CV outcome of death, myocardial infarction, or stroke (MACE-3), which is required to claim superiority versus an imputed placebo, the lower bound of efficacy of dulaglutide compared with placebo was estimated using a hierarchical Bayesian meta-analysis of placebo-controlled CVOTs of GLP-1 RAs. SURPASS CVOT was designed so that when the observed upper bound of the 95% confidence interval of the hazard ratio is less than the lower bound of efficacy of dulaglutide, it demonstrates non-inferiority to dulaglutide by preserving at least 50% of the CV benefit of dulaglutide as well as statistical superiority of tirzepatide to a theoretical placebo (imputed placebo analysis). The presented methods adding imputed placebo comparison for efficacy assessment may serve as a model for the statistical design of future active-controlled CVOTs., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
18. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
- Author
-
Bucheit J, Ayers J, Pamulapati L, Browning A, and Sisson E
- Subjects
- Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1 adverse effects, Humans, Hypoglycemic Agents adverse effects, Incretins adverse effects, Cardiovascular Diseases diagnosis, Cardiovascular Diseases drug therapy, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 drug therapy
- Abstract
Abstract: The incretin hormone system is the target of multiple type 2 diabetes mellitus (T2DM) treatments because defects in this system play major roles in the pathogenesis of diabetes. Currently, the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended for patients with atherosclerotic cardiovascular (CV) disease and those at high risk for atherosclerotic CV disease. In addition to the favorable CV effects, GLP-1 RAs also provide robust lowering of hemoglobin A1c and weight. Although these factors make GLP-1 RAs attractive options for T2DM, the currently available agents have no effect on glucose-dependent insulinotropic polypeptide (GIP). Patients with T2DM are known to have GIP defect which is significant due to its profound insulinotropic effects. Tirzepatide is a novel incretin agent currently recently approved by the Food and Drug Administration for the treatment of T2DM. This first-in-class agent serves as a coagonist for both the GLP-1 and GIP receptors. In this review, we report on the pharmacologic mechanism of GLP-1, GIP, and coagonist effects on the cardiometabolic system. In addition, we review the glycemic lowering, weight loss effects, and other cardiometabolic outcomes of tirzepatide based on phase 2 and 3 data. The safety profile of tirzepatide is consistent across all phase 3 trials. The most common adverse effects are gastrointestinal symptoms, but they generally have a low risk for discontinuation. Overall, preliminary data suggest that tirzepatide is an efficacious and safe agent for the treatment of T2DM., Competing Interests: The authors report no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
- Author
-
Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, and Gamble JM
- Subjects
- Alberta, Cohort Studies, Glucagon-Like Peptide 1 adverse effects, Glucose, Humans, Hypoglycemic Agents adverse effects, Insulin adverse effects, Propensity Score, Sodium adverse effects, Sulfonylurea Compounds adverse effects, Diabetes Mellitus, Type 2 chemically induced, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Thiazolidinediones adverse effects, Urinary Tract Infections chemically induced, Urinary Tract Infections complications, Urinary Tract Infections epidemiology
- Abstract
Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced glycosuria is hypothesized to increase the risk of urinary tract infections (UTIs). We assessed the risk of UTIs associated with SGLT2 inhibitor initiation in type 2 diabetes., Methods: We conducted a population-based cohort study using primary care data from the United Kingdom's Clinical Practice Research Datalink (CPRD) and administrative health-care data from Alberta, Canada. From a base cohort of new metformin users, we constructed 5 comparative cohorts, wherein the exposure contrast was defined as new use of SGLT2 inhibitors or 1 of 5 active comparators: dipeptidylpeptidase-4 (DPP-4) inhibitors, sulfonylureas (SU), glucagon-like peptide-1 receptor agonists (GLP-1 RA), thiazolidinediones (TZD) and insulin. We defined a composite UTI outcome based on hospitalizations or physician visit records. For each comparative cohort, we used high-dimensional propensity score matching to adjust for confounding and Cox proportional hazards regression to estimate the hazard ratios (HRs) in each database. We meta-analyzed estimates using a random-effects model., Results: SGLT2 inhibitor use was not associated with a higher risk of UTI compared with DPP-4 inhibitors (pooled HR, 1.08; 95% confidence interval [CI], 0.89 to 1.30), SU (pooled HR, 1.08; 95% CI, 0.90 to 1.30), GLP-1 RA (pooled HR, 0.81; 95% CI, 0.61 to 1.09) or TZD (pooled HR, 0.81; 95% CI, 0.55 to 1.19). The risk of UTI was lower compared with insulin (pooled HR, 0.74; 95% CI, 0.63 to 0.87). The risk of UTI did not differ based on the SGLT2 inhibitor agent or dose. Last, SGLT2 inhibitor initiation was not associated with an increased risk of UTI recurrence., Conclusion: SGLT2 inhibitor use is not associated with an increased risk of UTIs, compared with other antidiabetic agents., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
- Author
-
De Block CEM, Dirinck E, Verhaegen A, and Van Gaal LF
- Subjects
- Blood Glucose, Gastric Inhibitory Polypeptide therapeutic use, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor agonists, Humans, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 chemically induced, Diabetes Mellitus, Type 2 drug therapy, Receptors, Glucagon
- Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become agents of choice for people with type 2 diabetes (T2D) with established cardiovascular disease or in high-risk individuals. With currently available GLP-1 RAs, 51%-79% of subjects achieve an HbA1c target of less than 7.0% and 4%-27% lose 10% of body weight, illustrating the need for more potent agents. Three databases (PubMed, Cochrane, Web of Science) were searched using the MESH terms 'glucagon-like peptide-1 receptor agonist', 'glucagon receptor agonist', 'glucose-dependent insulinotropic peptide', 'dual or co-agonist', and 'tirzepatide'. Quality of papers was scored using PRISMA guidelines. Risk of bias was evaluated using the Cochrane assessment tool. An HbA1c target of less than 7.0% was attained by up to 80% with high-dose GLP-1 RAs and up to 97% with tirzepatide, with even up to 62% of people with T2D reaching an HbA1c of less than 5.7%. A body weight loss of 10% or greater was obtained by up to 50% and up to 69% with high-dose GLP-1 RAs or tirzepatide, respectively. The glucose- and weight-lowering effects of the GLP-1/glucagon RA cotadutide equal those of liraglutide 1.8 mg. Gastrointestinal side effects of high-dose GLP-1 RAs and co-agonists occurred in 30%-70% of patients, mostly arising within the first 2 weeks of the first dose, being mild or moderate in severity, and transient. The development of high-dose GLP-1 RAs and the dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide resulted in increasing numbers of people reaching HbA1c and body weight targets, with up to 62% attaining normoglycaemia with 15-mg tirzepatide. Whether this will also translate to better cardiovascular outcomes and affect treatment guidelines remains to be studied., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
21. Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Author
-
Sanz Segura P, Arguedas Lázaro Y, Mostacero Tapia S, Nerín de la Puerta JM, and Sebastián Domingo JJ
- Subjects
- Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptides, Humans, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Gastric Dilatation chemically induced, Gastric Dilatation complications
- Published
- 2022
- Full Text
- View/download PDF
22. Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.
- Author
-
Mandour DA, Shalaby SM, and Bendary MA
- Subjects
- Animals, Exenatide pharmacology, Exenatide therapeutic use, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 metabolism, Humans, Hyperalgesia metabolism, Male, Oxidative Stress, Rats, Signal Transduction, Spinal Cord metabolism, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Type 2 chemically induced, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism
- Abstract
The mechanisms of spinal cord-wide structural and functional disruption in diabetic patients remain elusive. This study evaluated histopathological alterations of the spinal cord cytoarchitecture in T2DM model of rats and assessed the potential ameliorating effect of exenatide "a potent GLP-1 analogue". Thirty male rats were allocated into three groups; I (control), II (Diabetic): T2DM was induced by high fat diet for 8 weeks followed by a single I.P injection of STZ (25 mg/kg BW) and III (Diabetic/Exenatide): T2DM rats injected with exenatide (10 μg/Kg, S.C. twice daily for 2 weeks). Neurobehavioral sensory and motor tests were carried out and glycemic control biomarkers and indices of insulin resistance and sensitivity were measured. In addition, the spinal cord was processed for histological and immunohistochemical studies besides assessing its tissue homogenate levels of pro-inflammatory/anti-inflamatory cytokines and oxidant/antioxidant biomarkers. Moreover, RT-qPCR was performed to measure the expression of proapoptotic/antiapoptotic and neurotrophic genes. The diabetic rats exhibited thermal hyperalgesia, mechanical allodynia and decreased locomotor activity along with increased serum glucose, insulin, HbA1c, HOMA-IR while, quantitative insulin sensitivity check index (QUICKI) was decreased. Also, IL-1β NF-kB, MDA increased while IL-10, SOD activity and β-endorphin decreased in the spinal tissue. Up regulation of caspase-3 and down regulation of Bcl-2, nerve growth factor (NGF) and glial cell-derived neurotrophic (GDNF) in diabetic rats. Also, they exhibited histopathological changes and increased CD68 positive microglia and Bax immunoreactivity in the spinal cord. Subsequent to exenatide treatment, most biomolecular, structural and functional impairments of the spinal cord were restored in the diabetic rats. In conclusion, the neuro-modulating effect of exenatide against diabetic-induced spinal cord affection warrants the concern about its therapeutic relevance in confronting the devastating diabetic neuropathic complications., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.
- Author
-
Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, and Acharya LD
- Subjects
- Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents adverse effects, Liraglutide, Diabetes Mellitus, Type 2, Drug-Related Side Effects and Adverse Reactions epidemiology
- Abstract
Background and Aim: The importance of glucagon-like peptide-1 (GLP-1) agonists is increasing because of its blood sugar controlling and weight loss properties. The data regarding safety of GLP-1 agonists are limited. This study aims to review case reports and case series on adverse drug reactions (ADRs) of GLP-1 agonist., Methodology: A comprehensive search was performed in PubMed/Medline, Scopus and Embase to identify literatures. Bibliographic search and open search in Google, Google Scholar, SpringerLink and ResearchGate was performed to identify additional studies. Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study. Reviews, experimental studies, observational studies, grey literature and non English studies were excluded., Results: The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2). The major ADRs reported was gastrointestinal disorders (n = 40) followed by renal (n = 23), dermatologic (n = 14), hepatic (n = 10), immunologic (n = 13), endocrine/metabolic (n = 7), hematologic (n = 3), angioedema (n = 3), neurologic (n = 2), cardiovascular (n = 2) and 1 from each of psychiatric, reproductive, generalized edema problems., Conclusion: Gastrointestinal problems, particularly pancreatitis was the more frequently reported adverse drug reaction associated with GLP-1 agonist. The most adverse drug reactions were observed with liraglutide and exenatide., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
24. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine.
- Author
-
Klemettilä JP, Solismaa A, Seppälä N, Hämäläinen M, Moilanen E, Leinonen E, and Kampman O
- Subjects
- Female, Glucagon-Like Peptide 1 adverse effects, Humans, Male, Obesity, Weight Gain, Clozapine adverse effects, Diabetes Mellitus, Type 2 complications
- Abstract
Metabolic syndrome and related cardiovascular risk factors are well-known comorbidities among patients with schizophrenia. Biomarkers of these antipsychotic-associated metabolic adverse effects and antipsychotic-induced weight gain are needed. Glucagon-like peptide-1 (GLP-1) is involved in insulin secretion, regulation of satiety, inhibition of food intake, and inhibition of gastric emptying. GLP-1 also induces reduction in body weight. Visfatin/ NAMPT/ PBEF is an adipocytokine secreted by several cells and tissues. Increased plasma visfatin levels have been associated with overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases, low grade inflammation, and proinflammatory markers. Associations between antipsychotic-induced weight gain and serum visfatin and GLP-1 levels have been little studied in patients with schizophrenia. The aim of the present study was to test the possible role of serum GLP-1 and visfatin level alterations as markers of weight gain in association with metabolic and inflammatory markers in 190 patients (109 male, 81 female) with schizophrenia on clozapine treatment. High serum levels of GLP-1 correlated significantly with higher levels of visfatin, leptin, insulin, HOMA-IR, higher BMI, and weight change among men. Associations between serum visfatin levels and BMI or weight change were not found in the present patients. Serum GLP-1 level seems to be a marker of metabolic risk factors among men with schizophrenia on clozapine treatment. Female patients may be more sensitive to suppressive effects of clozapine on GLP-1 secretion. Patients on clozapine would benefit from GLP-1 agonists as preventive treatment., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
25. Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus.
- Author
-
Fauchier G, Bisson A, Bodin A, Herbert J, Angoulvant D, Ducluzeau PH, Lip GYH, and Fauchier L
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation diagnosis, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Female, Glucagon-Like Peptide 1 adverse effects, Humans, Insulin adverse effects, Male, Metformin adverse effects, Middle Aged, Risk Assessment, Sulfonylurea Compounds adverse effects, Atrial Fibrillation chemically induced, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents adverse effects
- Published
- 2021
- Full Text
- View/download PDF
26. Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.
- Author
-
Maringwa J, Sardu ML, Hang Y, Czerniak R, Vishnubhotla M, Vakilynejad M, and Pfister M
- Subjects
- Animals, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Gastric Inhibitory Polypeptide adverse effects, Gastric Inhibitory Polypeptide agonists, Gastric Inhibitory Polypeptide therapeutic use, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 agonists, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents therapeutic use, Blood Pressure drug effects, Heart Rate drug effects, Hypoglycemic Agents adverse effects
- Abstract
A model-based meta-analysis was performed with reported data from obese subjects and patients with type 2 diabetes (T2DM) to characterize the effects of dipeptidyl peptidase 4 (DPP4) inhibitors, gastric inhibitory polypeptides (GIPs), glucagon-like peptide-1 (GLP1), and dual GIP/GLP1 agonists, or a combination of these antidiabetic drugs (ADs) on heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP). A systematic literature search and review after the Cochrane method identified sources for investigational and approved ADs resulted in a comprehensive database with data from 178 clinical studies in obese subjects and patients with T2DM. Results indicated that there were AD class-dependent effects on HR and SBP, whereas no clear AD-related effects on DBP were found. All AD classes, except for DPP4 inhibitors, increased HR. The largest increase of 12 bpm was seen with GLP1 receptor agonists. All AD classes appeared to decrease SBP. DPP4 inhibitors were associated with a marginal decrease of ~ 1 mmHg, whereas GLP1 and GIP/GLP1 dual agonists exhibited the largest decrease of ~ 3 mmHg in SBP. AD-related effects were similar in obese subjects and patients with T2DM. In conclusion, there are clinically relevant AD-related effects on both HR and SBP, but not on DBP. DPP4 inhibitors are associated with the smallest (if at all) effects on HR and SBP, whereas GLP1 inhibitors exhibited the largest effects on these two cardiovascular end points. Additional studies are warranted to further investigate how AD-related SBP decreases combined with HR increases affect long-term cardiovascular mortality., (© 2020 The Authors. Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2021
- Full Text
- View/download PDF
27. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
- Author
-
Rosenstock J, Nino A, Soffer J, Erskine L, Acusta A, Dole J, Carr MC, Mallory J, and Home P
- Subjects
- Adult, Aged, Blood Glucose drug effects, Diabetes Mellitus, Type 2 blood, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Insulin adverse effects, Insulin Glargine administration & dosage, Insulin Lispro administration & dosage, Male, Meals, Middle Aged, Treatment Failure, Young Adult, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glycemic Control methods, Insulin administration & dosage
- Abstract
Objective: The principle of replacing prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) for type 2 diabetes inadequately controlled on a multiple daily insulin injections regimen was tested with albiglutide., Research Design and Methods: In this treat-to-target study, basal plus prandial insulin was optimized over 4 weeks before participants were randomized (1:1) to albiglutide plus optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; subsequently, lispro injections were fully discontinued 4 weeks later) ( n = 402) or to continued optimized lispro plus optimized glargine ( n = 412)., Results: Mean ± SD HbA
1c at baseline, 7.8 ± 0.6% (61 ± 7 mmol/mol) in the albiglutide + glargine group and 7.7 ± 0.6% (60 ± 7 mmol/mol) in the lispro + glargine group, was reduced at week 26 to 6.7 ± 0.8% (49 ± 8 mmol/mol) and 6.6 ± 0.8% (48 ± 8 mmol/mol), respectively (least squares [LS] difference 0.06% [95% CI -0.05 to 0.17]; noninferiority P < 0.0001). In the albiglutide + glargine group, 218 participants (54%) replaced all prandial insulin without reintroducing lispro up to week 26. Total daily prandial insulin dose was similar at baseline but was lower by 62 units/day (95% CI -65.9 to -57.8; P < 0.0001) at week 26 in the albiglutide + glargine group, and the total number of weekly injections was also reduced from 29 to 13 per week. Less severe/documented symptomatic hypoglycemia (57.2% vs. 75.0%) occurred in the albiglutide + glargine group with meaningful weight differences (LS mean ± SE -2.0 ± 0.2 vs. +2.4 ± 0.2 kg; P < 0.0001) vs. lispro + glargine. Gastrointestinal adverse events were higher with albiglutide + glargine (26% vs. 13%)., Conclusions: A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm. Replacing prandial insulin with a weekly GLP-1RA can simplify basal plus prandial insulin treatments and achieve better outcomes in type 2 diabetes., (© 2020 by the American Diabetes Association.)- Published
- 2020
- Full Text
- View/download PDF
28. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
- Author
-
Bækdal TA, Borregaard J, Hansen CW, Thomsen M, and Anderson TW
- Subjects
- Administration, Oral, Adult, Aged, Angiotensin-Converting Enzyme Inhibitors pharmacokinetics, Anticoagulants pharmacokinetics, Cardiotonic Agents pharmacokinetics, Case-Control Studies, Cross-Over Studies, Digoxin pharmacokinetics, Drug Interactions, Female, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptides adverse effects, Healthy Volunteers, Humans, Hypoglycemic Agents pharmacokinetics, Lisinopril pharmacokinetics, Male, Metformin pharmacokinetics, Middle Aged, Warfarin pharmacokinetics, Caprylates administration & dosage, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptides administration & dosage, Glucagon-Like Peptides pharmacology
- Abstract
Background: Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs may be altered due to enhancement by SNAC, potential gastric emptying delay by semaglutide, or other mechanisms. Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin., Methods: In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state). In trial 2, 32 healthy subjects received digoxin (500 μg single dose) or metformin (850 mg twice daily for 4 days), with subsequent coadministration with SNAC alone followed by oral semaglutide, as in trial 1., Results: There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C
max ) for lisinopril, warfarin, and digoxin. The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the Cmax was unaffected. SNAC alone did not affect exposure of lisinopril, warfarin, digoxin, or metformin. Adverse events were in line with those previously observed for GLP-1 receptor agonists., Conclusions: Oral semaglutide or SNAC alone did not appear to affect the exposure of lisinopril, warfarin, or digoxin, and, based on its wide therapeutic index, the higher metformin exposure with oral semaglutide was not considered clinically relevant.- Published
- 2019
- Full Text
- View/download PDF
29. PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
- Author
-
Al-Kawas F, Anderson MA, Enns R, Wilson TH, Johnson S, and Mallory JM
- Subjects
- Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Middle Aged, Pancreas, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1 analogs & derivatives
- Abstract
Objective: Albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), reduces glycated hemoglobin with a low risk of hypoglycemia in patients with type 2 diabetes. The relationship between GLP-1RAs and risk of pancreatitis is unresolved. This independent, rigorous, expert review of the albiglutide HARMONY Phase III clinical program examined suspected cases of acute pancreatitis. Methods: An independent pancreatitis adjudication committee (PAC), composed of physicians with expertise in gastroenterology and pancreatic disease, was prospectively established to review cases of suspected acute pancreatitis in the HARMONY studies. Results: Patients treated in Phase III trials with albiglutide (n = 2,365), or active or placebo comparators (n = 2,530), averaged 56 years of age with a mean 8.3-year diabetes duration. Across the 8 studies, the PAC reviewed potential cases of treatment-emergent acute pancreatitis in 43 patients. Definite or probable acute pancreatitis was adjudicated for 11 patients (8 albiglutide; 3 active comparators). Most of these were considered by the PAC to be at least possibly related to study treatment (6 of 8 albiglutide cases and 2 of 3 active comparator cases). Both cases in the active comparator group adjudicated as definite or probable pancreatitis with at least a possible relationship to study treatment were in patients treated with a GLP-1RA. The frequency of pancreatitis was higher among patients treated with albiglutide (6/2,365, 0.3%) than with placebo (0/486, 0%) or active comparators (2/2,062, 0.08%). Conclusion: In the HARMONY Phase III program, adjudicated cases of acute pancreatitis were uncommon. However, within the limitations of available data, the incidence of acute pancreatitis with albiglutide appears to be within the range described for other studies of GLP-1RAs. Abbreviations: AE = adverse event; CI = confidence interval; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; GLP-1RA = glucagon-like peptide-1 receptor agonist; MH-OR = Mantel-Haenszel odds ratio; OR = odds ratio; PAC = pancreatitis adjudication committee; SAE = serious adverse event; ULN = upper limit of normal.
- Published
- 2019
- Full Text
- View/download PDF
30. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
- Author
-
Shaddinger BC, Soffer J, Vlasakakis G, Shabbout M, Weston C, and Nino A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose drug effects, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Compounding, Female, Freeze Drying, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glycated Hemoglobin analysis, Glycated Hemoglobin drug effects, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Male, Metformin administration & dosage, Metformin adverse effects, Middle Aged, Solutions, Treatment Outcome, Young Adult, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives
- Abstract
Aims: Compare the efficacy and safety of albiglutide from a ready-to-use, single-dose, auto-injector system with the lyophilized product in patients with type 2 diabetes mellitus (T2DM)., Methods: In this phase 3 study, 308 patients between 18 and 80 years with T2DM and experiencing inadequate glycemic control on their current regimen of diet/exercise alone or in combination with metformin were randomized 1:1 to weekly injections for 26 weeks with an active albiglutide auto-injector and placebo lyophilized dual-chamber cartridge (DCC) pen injector (n = 154) or active albiglutide lyophilized DCC pen injector and placebo liquid auto-injector (n = 154). Participants received liquid or lyophilized albiglutide 30 mg for 4 weeks, and then 50 mg for the remaining 22 weeks. Change in HbA
1c and fasting plasma glucose (FPG), pharmacokinetics, and safety were assessed., Results: In the albiglutide liquid and lyophilized drug product groups, 55.6% (85/153) and 45.5% of patients (70/154) had a baseline HbA1c ≥ 8.0%, respectively. The model-adjusted least squares (LS) mean change in HbA1c from baseline at week 26 was -1.1% (95% CI: -1.3, -1.0) and -1.2% (95% CI: -1.3, -1.0; noninferiority P = 0.0002) in the albiglutide liquid and lyophilized product groups, respectively. Similarly, the model-adjusted LS mean change in FPG from baseline at week 26 in the albiglutide liquid and lyophilized product groups was -2.2 (95% CI: -2.6, -1.8) mmol/L and -1.9 (95% CI: -2.3, -1.5) mmol/L, respectively. No new safety concerns were identified., Conclusion: Change from baseline in HbA1c for albiglutide liquid was noninferior to lyophilized drug product in patients with T2DM., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
31. A Randomized, Double-Blind, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants.
- Author
-
Shaddinger BC, Vlasakakis G, Soffer J, Thorpe KM, Hatch D, and Nino AJ
- Subjects
- Adolescent, Adult, Aged, Antibodies, Neutralizing blood, Area Under Curve, Biological Availability, Cross-Over Studies, Diabetes Mellitus, Type 2 drug therapy, Double-Blind Method, Drug Delivery Systems instrumentation, Drug Delivery Systems methods, Female, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 blood, Half-Life, Healthy Volunteers, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Immunoglobulin E blood, Male, Middle Aged, Young Adult, Glucagon-Like Peptide 1 analogs & derivatives, Hypoglycemic Agents blood
- Abstract
Albiglutide, developed for treatment of type 2 diabetes mellitus, is provided in a dual-chamber cartridge (DCC) single-dose pen-injector containing lyophilized drug that must be reconstituted with diluent prior to use. A liquid formulation of albiglutide has been developed that does not require mixing. In this 2-period, randomized, crossover, double-blind, phase I study (NCT02660736) in 59 healthy volunteers, pharmacokinetic parameters were determined and the bioequivalence of the 2 formulations was assessed. Participants received injections from each type of pen-injector, one containing albiglutide 50 mg and one containing placebo, followed by an 8-week washout period between regimens: albiglutide 50-mg liquid formulation from an auto-injector and lyophilized placebo from a DCC pen-injector (Regimen A), or placebo liquid from an auto-injector and lyophilized albiglutide 50 mg from a DCC pen-injector (Regimen B). Geometric mean total exposures (area under the drug concentration-time curve [AUC]
(0-t) [1345.4 vs 1426.9 (μg · h/mL)], AUC(0-∞) [1376.2 vs 1454.6 (μg · h/mL)], and maximum concentration of drug in blood plasma [4968.5 vs 5314.7 ng/mL]) were comparable between Regimens A and B. Ratios of geometric least square means (90% confidence interval) were 95.3% (89.49-101.52) for AUC(0-∞) , 95.1% (89.12-101.49) for AUC(0-t) , and 93.2% (86.76-100.17) for maximum concentration of drug in blood plasma, falling within the 90% confidence interval of 0.80 to 1.25 for bioequivalence. No new safety concerns were observed., (© 2018, The American College of Clinical Pharmacology.)- Published
- 2019
- Full Text
- View/download PDF
32. Potential Issues With New Basal Insulin/GLP-1 Fixed Combinations.
- Author
-
Shastay A
- Subjects
- Blood Glucose drug effects, Diabetes Mellitus, Type 2 diagnosis, Dose-Response Relationship, Drug, Drug Combinations, Female, Glucagon-Like Peptide 1 adverse effects, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Insulin Aspart adverse effects, Insulin, Long-Acting adverse effects, Male, Risk Assessment, United States, United States Food and Drug Administration, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 administration & dosage, Insulin Aspart administration & dosage, Insulin, Long-Acting administration & dosage, Patient Safety
- Published
- 2019
- Full Text
- View/download PDF
33. [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
- Author
-
Sun XF, Wang Y, Zhao WJ, Wang L, Bao DQ, Qu GR, Yao MX, Luan J, Wang YG, and Yan SL
- Subjects
- Blood Glucose drug effects, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Glucagon metabolism, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents adverse effects, Insulin, Prospective Studies, Treatment Outcome, Blood Glucose metabolism, Diabetes Mellitus, Type 2 drug therapy, Glucagon drug effects, Glycated Hemoglobin metabolism, Hypoglycemic Agents administration & dosage, Liraglutide pharmacology, Obesity complications, Postprandial Period physiology
- Abstract
Objective: To investigate the effect of liraglutide on glucagon release in obese type 2 diabetes (T2DM). Methods: A multi-center, prospective, and self-comparison study was conducted in four hospitals in Qingdao. Twenty-four patients with T2DM were selected and treated with liraglutide for 12 weeks. Glucagon levels before and after treatment were detected before and 30 min, 60 min and 120 min after meals. Results: After 12 weeks of treatment, the overall level of glucagon decreased, in which the differences in glucagon levels at 30 min [(220±79) ng/L vs. (203±77) ng/L, P< 0.05] and 60 min [(248±119) ng/L vs. (203±82)ng/L, P< 0.05] reached significance, respectively, comparing to those before treatment. The area under the curve of glucagon after treatment was significantly lower than that before treatment (438±190 vs. 389±153, P< 0.05). In contrast, after treatment, the overall level of C-peptide increased, especially the levels at 30 min [(1.53±1.02) nmol/L vs.(2.03±1.29) nmol/L], 60 min [(1.93±1.19) nmol/L vs. (2.48±1.75) nmol/L] and 120 min [(2.36±1.47) nmol/L vs. (2.96±1.84) nmol/L], all P< 0.05. The area under C-peptide curve increased significantly (3.6±2.2 vs. 4.6±2.9, P< 0.05). Fasting plasma glucose, postprandial 2 h plasma glucose and glycosylated hemoglobin A1c were all lower than before, and the differences were statistically significant ( P< 0.05). Waist circumference and body mass index were significantly lower than before ( P< 0.05). The amount of insulin used for the treatment decreased by approximately 55.1% compared with that before liraglutide, and the difference was statistically significant ( P< 0.05). Conclusions: Liraglutide inhibits glucagon secretion and lowers blood glucose. It can also reduce body weight, improve islet cell function and reduce insulin use in T2DM.
- Published
- 2019
- Full Text
- View/download PDF
34. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
- Author
-
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, and Jermutus L
- Subjects
- Adult, Aged, Blood Glucose drug effects, Body Mass Index, Diabetes Mellitus, Type 2 complications, Double-Blind Method, Female, Glucagon-Like Peptide 1 adverse effects, Glycated Hemoglobin drug effects, Humans, Hypoglycemic Agents adverse effects, Injections, Subcutaneous, Male, Middle Aged, Obesity complications, Peptides adverse effects, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 administration & dosage, Hypoglycemic Agents administration & dosage, Obesity drug therapy, Peptides administration & dosage, Weight Loss drug effects
- Abstract
Background: Weight loss is often key in the management of obese or overweight patients with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like peptide-1 and glucagon receptor dual agonist developed to provide glycaemic control and weight loss, in patients with type 2 diabetes., Methods: This randomised, placebo-controlled, double-blind, combined multiple-ascending dose (MAD) and phase 2a study was done at 11 study sites (hospitals and contract research organisations) in Germany. We enrolled patients aged 18-65 years with controlled type 2 diabetes (glycated haemoglobin A
1c [HbA1c ] levels of 6·5-8·5% at screening) and a body-mass index between 27 kg/m2 and 40 kg/m2 . An interactive web-response system was used to randomly assign patients to receive MEDI0382 or placebo. Patients were randomly assigned 2:1 in cohorts A-C and 3:1 in cohorts D and E in the MAD portion of the study, and 1:1 in the phase 2a portion. Randomisation was done by a contracted third-party operator who was not involved in the clinical operations of the study. The pharmacists, participants, and study site personnel involved in treating and assessing participants were masked to treatment allocation. Patients received once-daily subcutaneous injections of the study drug at doses of no more than 300 μg for 22 days or less in the MAD portion of the study, and a dose of no more than 200 μg for 41 days or less in the phase 2a portion. The two primary endpoints of the phase 2a portion were the change from baseline to day 41 in glucose area under the curve at 0-4 h (AUC0-4 h ) after a mixed-meal tolerance test (MMTT), assessed in all participants who received at least one dose of study drug and whose measurements were taken at baseline and day 41, and change from baseline in bodyweight, assessed in the intention-to-treat (ITT) population. Safety analyses were done in all participants who received any study drug analysed according to the treatment they received. This study is registered with ClinicalTrials.gov, number NCT02548585., Findings: Patients were recruited between Dec 9, 2015, and Feb 24, 2017. 61 patients were randomly assigned to the MAD part of the study (42 to MEDI0382 and 19 to placebo). 51 patients were randomly assigned to the phase 2a part, of whom 25 were randomly assigned to MEDI0382 and 26 to placebo. In the phase 2a study, three patients in the MEDI0382 group and one in the placebo group discontinued, all as a result of adverse events. 22 (88%) patients in the MEDI0382 group and 25 (96%) in the placebo group received at least one dose and had measurements taken at baseline and day 41. Glucose AUC0-4 h post MMTT decreased significantly with MEDI0382 versus placebo (least squares [LS] mean -32·78% [90% CI -36·98 to -28·57] vs -10·16% [-14·10 to -6·21], and the mean difference was -22·62% [-28·40 to -16·85]; p<0·0001). In the ITT population, reduction in bodyweight was significantly greater with MEDI0382 than with placebo (LS mean -3·84 kg [90% CI -4·55 to -3·12] vs -1·70 kg [-2·40 to -1·01] and mean difference of 2·14 kg [-3·13 to -1·31]; p=0·0008). The proportion of patients who had a treatment-emergent adverse event (TEAE) was similar between treatment groups (22 [88%] of 25 in the MEDI0382 group vs 23 [88%] of 26 in the placebo group); gastrointestinal disorders (18 [72%] vs 13 [40%]) and decreased appetite (five [20%] vs none) occurred more frequently with MEDI0382 than placebo. No participants in the MEDI0382 group had a grade 3 or worse TEAE (vs two [8%] in the placebo group)., Interpretation: MEDI0382 has the potential to deliver clinically meaningful reductions in blood glucose and bodyweight in obese or overweight individuals with type 2 diabetes., Funding: MedImmune., (Copyright © 2018 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
35. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
- Author
-
Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, and Lefebvre P
- Subjects
- Electronic Health Records statistics & numerical data, Female, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Male, Middle Aged, Patient Preference statistics & numerical data, Retrospective Studies, Treatment Outcome, United States epidemiology, Blood Pressure drug effects, Body Weight drug effects, Canagliflozin administration & dosage, Canagliflozin adverse effects, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide-1 Receptor agonists
- Abstract
Objective: To compare achievement of quality goals (HbA1c, weight loss/body mass index [BMI], systolic blood pressure [SBP]), including maintaining HbA1c, between patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin 300 mg (CANA) or a GLP-1 in an actual practice setting., Methods: Adults with T2DM newly initiated on CANA or a GLP-1 were identified from the IQVIA
TM Real-World Data Electronic Medical Records-US database (2012Q2-2016Q1). To account for differences in baseline characteristics, inverse probability of treatment weighting was used. Outcomes were compared using Cox models (hazard ratios [HRs] and 95% confidence intervals [CIs]) and Kaplan-Meier analyses., Results: CANA (n = 11,435) and GLP-1 (n = 11,582) cohorts had similar attainment of HbA1c < 8.0% (64 mmol/mol) and HbA1c < 9.0% (75 mmol/mol; HbA1c < 8.0%: HR [CI] = 0.98 [0.91-1.06]; HbA1c < 9.0%: HR [CI] = 1.02 [0.93-1.12]), while GLP-1 patients were 10% more likely to achieve HbA1c < 7.0% (53 mmol/mol). CANA and GLP-1 patients were similar in maintaining HbA1c < 7.0%, < 8.0%, or <9.0%, achieving weight loss ≥5% (HR [CI] = 1.05 [0.99-1.12]), achieving BMI <30 kg/m2 (HR [CI] = 1.11 [0.98-1.27]), and achieving SBP <140 mmHg (HR [CI] = 1.07 [0.98-1.17]). CANA patients were 30% less likely to discontinue treatment, 28% less likely to have a prescription for a new anti-hyperglycemic, and 17-21% less likely to fail to maintain HbA1c < 8.0% or 9.0% or have a prescription for a new anti-hyperglycemic (composite outcome) vs GLP-1. No significant difference was observed for the composite outcome using the HbA1c < 7.0% threshold., Conclusions: This retrospective study in an actual practice setting showed that CANA patients were generally as likely as GLP-1 patients to achieve HbA1c, weight, and blood pressure thresholds, and to maintain glycemic control while being less likely to discontinue treatment and/or have a new anti-hyperglycemic prescribed.- Published
- 2018
- Full Text
- View/download PDF
36. Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Author
-
Frias JP
- Subjects
- Blood Glucose drug effects, Delayed-Action Preparations administration & dosage, Drug Administration Schedule, Drug Monitoring methods, Exenatide adverse effects, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptides administration & dosage, Glucagon-Like Peptides adverse effects, Humans, Hypoglycemia chemically induced, Hypoglycemic Agents administration & dosage, Immunoglobulin Fc Fragments administration & dosage, Randomized Controlled Trials as Topic, Recombinant Fusion Proteins administration & dosage, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptides analogs & derivatives, Hypoglycemic Agents adverse effects, Immunoglobulin Fc Fragments adverse effects, Recombinant Fusion Proteins adverse effects
- Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been found efficacious in the treatment of type 2 diabetes (T2D), demonstrating the ability to lower HbA1c, and having the potential for inducing weight loss and reducing the risk of hypoglycemia, compared with other antihyperglycemic agents. Currently, 4 once-weekly (OW) GLP-1 RAs are approved: albiglutide, dulaglutide, exenatide ER, and recently, semaglutide. This review compares the relative safety of OW GLP-1 RAs, as well as their safety in comparison to other antihyperglycemic agents, using safety data reported in key sponsor-led phase 3 studies of the 4 OW GLP-1 RAs. The favorable safety profiles of OW GLP-1 RAs, added to their efficacy and the favorable weekly dosing regimen, make these agents appropriate options for patients with T2D. However, there are key differences within this class of drugs in macrovascular, microvascular, gastrointestinal and injection-site reaction adverse events, and these should be considered when healthcare providers are prescribing therapy.
- Published
- 2018
37. Don't Play with Your Nodule: Case Report of Tachycardia and Other Adverse Reactions from Manipulation of an Exenatide Injection Site Nodule.
- Author
-
Sandman C, Krainin B, and Roper J
- Subjects
- Chest Pain etiology, Diabetes Mellitus, Type 2 complications, Diarrhea etiology, Emergency Service, Hospital organization & administration, Exenatide therapeutic use, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Injection Site Reaction, Male, Middle Aged, Nausea etiology, Diabetes Mellitus, Type 2 drug therapy, Exenatide administration & dosage, Exenatide adverse effects, Tachycardia etiology
- Abstract
Background: Type II diabetes mellitus (DM) is an increasingly prevalent cause of morbidity and mortality among U.S. adults, with increasing prevalence in emergency department (ED) visits. Multiple medications, such as exenatide, a glucagon-like peptide-1 agonist, have been developed in the past decade to combat this growing problem. This medication is well documented to cause gastrointestinal upset and skin nodules at the injection site. However, currently no documented cases exist regarding manipulation of injection nodules causing increased absorption or reports demonstrating an increase in adverse drug reactions., Case Report: We report an interesting case of an adult male patient who likely experienced increased systemic absorption of exenatide by manipulating an injection nodule, which ultimately resulted in nausea, retching, diarrhea, and a tachycardic heart rate of 130-140 beats/min. These symptoms are known side effects of exenatide. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Given the high frequency of DM patients presenting to the ED, emergency physicians should be familiar with diabetic maintenance medications and their adverse reactions. Treating these side effects and properly educating patients can alleviate discomfort, prevent future adverse reactions, and decrease return visits to the ED., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
38. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
- Author
-
Drucker DJ
- Subjects
- Animals, Blood Glucose drug effects, Eating drug effects, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptide-1 Receptor physiology, Humans, Hypoglycemic Agents therapeutic use, Insulin metabolism, Mice, Rats, Weight Gain drug effects, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2 therapy, Glucagon-Like Peptide 1 pharmacology, Obesity therapy
- Abstract
Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion. GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting weight gain. Here I review the circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-positive cell types and pathways transducing metabolic and non-glycemic GLP-1 signals. The role(s) of GLP-1 in the benefits and side effects associated with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiology are highlighted. Refinement of the risk-versus-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimolecular multi-agonists, all targeting the GLP-1R. This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
39. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
- Author
-
Abrahami D, Yin H, Yu OHY, Pollak MN, and Azoulay L
- Subjects
- Aged, Databases, Factual, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Female, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents therapeutic use, Incidence, Incretins therapeutic use, Longitudinal Studies, Male, Medical Audit, Middle Aged, Proportional Hazards Models, United Kingdom epidemiology, Colorectal Neoplasms chemically induced, Colorectal Neoplasms epidemiology, Glucagon-Like Peptide 1 adverse effects, Incretins adverse effects
- Abstract
Background: Evidence on the safety of the incretin-based drugs (glucagon-like peptide-1 [GLP-1] analogues and dipeptidyl peptidase-4 [DPP-4] inhibitors) with respect to colorectal cancer is contradictory. The objective of this study was to determine whether use of incretin-based drugs is associated with risk of incident colorectal cancer in patients with type 2 diabetes., Methods: Using data from the UK Clinical Practice Research Datalink, we identified a cohort of 112,040 patients newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2015. We modeled use of GLP-1 analogues and DPP-4 inhibitors as time-varying variables and compared them with use of sulfonylureas. We lagged exposures by 1 year for latency and to reduce reverse causality and detection bias. We used time-dependent Cox proportional hazards models to estimate hazard ratios with 95% confidence intervals of incident colorectal cancer associated with the use of GLP-1 analogues and DPP-4 inhibitors overall, by cumulative duration of use and by time since initiation., Results: During 388,619 person-years of follow-up, there were 733 incident colorectal cancer events (incidence rate: 1.9 per 1,000 person-years). Use of GLP-1 analogues was not associated with colorectal cancer incidence (hazard ratio: 1.0; 95% confidence interval = 0.7, 1.6), nor was use of DPP-4 inhibitors (hazard ratio: 1.2; 95% confidence interval = 1.0, 1.5). There was no evidence of a duration-response relation for either drug., Conclusions: The results of this large population-based study indicate that use of incretin-based drugs is not associated with colorectal cancer incidence among patients with type 2 diabetes.
- Published
- 2018
- Full Text
- View/download PDF
40. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
- Author
-
Unni S, Wittbrodt E, Ma J, Schauerhamer M, Hurd J, Ruiz-Negrón N, and McAdam-Marx C
- Subjects
- Adult, Aged, Body Mass Index, Cohort Studies, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Drug Administration Schedule, Exenatide adverse effects, Exenatide therapeutic use, Female, Follow-Up Studies, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide-1 Receptor metabolism, Glucagon-Like Peptides administration & dosage, Glucagon-Like Peptides adverse effects, Glucagon-Like Peptides therapeutic use, Glycated Hemoglobin analysis, Humans, Hypoglycemia prevention & control, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Immunoglobulin Fc Fragments adverse effects, Immunoglobulin Fc Fragments therapeutic use, Male, Middle Aged, Obesity complications, Recombinant Fusion Proteins adverse effects, Recombinant Fusion Proteins therapeutic use, Retrospective Studies, Weight Loss drug effects, Diabetes Mellitus, Type 2 drug therapy, Exenatide administration & dosage, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptides analogs & derivatives, Hyperglycemia prevention & control, Hypoglycemic Agents administration & dosage, Immunoglobulin Fc Fragments administration & dosage, Recombinant Fusion Proteins administration & dosage
- Abstract
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real-world, 6-month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide and albiglutide. The study included 2465 patients: exenatide once weekly, n = 2133; dulaglutide, n = 201; and albiglutide, n = 131. The overall mean (standard deviation [s.d.]) age was 60 (11) years and 54% were men; neither differed among the comparison groups. The mean (s.d.) baseline HbA1c was similar in the exenatide once-weekly (8.3 [1.7]%) and dulaglutide groups (8.5 [1.5]%; P = .165), but higher in the albiglutide group (8.7 [1.7]%; P < .001). The overall mean (s.d.) HbA1c change was -0.5 (1.5)% (P < .001) and this did not differ among the comparison groups in either adjusted or unadjusted analyses. The mean (s.d.) weight change was -1.4 (4.7) kg for exenatide once weekly and -1.6 (3.7) kg for albiglutide (P = .579), but was greater for dulaglutide, at -2.7 (5.7) kg (P = .001). Outcomes were similar in subsets of insulin-naive patients with baseline HbA1c ≥7.0% or ≥9.0%. All agents significantly reduced HbA1c at 6 months, with no significant differences among agents or according to baseline HbA1c in insulin-naive subgroups., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
41. Albiglutide for the management of type 2 diabetes.
- Author
-
Rendell MS
- Subjects
- Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents pharmacology, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide-1 Receptor agonists, Hypoglycemic Agents therapeutic use
- Abstract
Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and approved for use in type 2 diabetes. It has less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as some competitor agents. Area covered: The current use of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long-term study is now underway to determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events. At present, albiglutide is a safe agent to introduce GLP-1 RA treatment into the regimen for type 2 diabetes patients and may be the GLP-1 agent of choice in patients with renal insufficiency.
- Published
- 2018
- Full Text
- View/download PDF
42. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
- Author
-
Davidson JA, Jones-Leone A, Wilson TH, Nino A, Forero-Schwanhaeuser S, and Reinhardt RR
- Subjects
- Adult, Aged, Blood Glucose, Body Mass Index, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Double-Blind Method, Drug Therapy, Combination, Female, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glycated Hemoglobin, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Insulin therapeutic use, Male, Middle Aged, Sulfonylurea Compounds therapeutic use, Thiazolidinediones therapeutic use, Weight Loss, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Hispanic or Latino, Hypoglycemic Agents therapeutic use
- Abstract
Objective: to evaluate the efficacy and safety of albiglutide compared with placebo and active comparators from an integrated trial subpopulation of Latino/Hispanic patients whose type 2 diabetes mellitus (T2DM) was inadequately controlled on their current regimen of diet and exercise, with or without oral antidiabetic drugs (OADs) and/or insulin., Methods: Latino/Hispanic patient subpopulations (N = 1204) across 7 phase III albiglutide studies (N = 4400) were evaluated post-hoc for efficacy and safety. Comparators were placebo, sulfonylureas, insulin, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors. Glycatedhemoglobin (HbA
1c ) change from baseline to the time of the primary endpoint assessment (from 26 to 104 weeks) was evaluated in patients on diet and exercise and/or OADs, with or without insulin. Patients were allowed to continue in the study if hyperglycemic rescue was required, according to a prespecified algorithm and at the discretion of the investigator., Results: At baseline in the Latino/Hispanic subpopulation, the mean HbA1c was 8.3%, mean age was 53 years, mean body mass index was 32 kg/m2 , and mean duration of T2DM was 8.0 years. The primary endpoint of mean HbA1c difference (albiglutide - placebo) was -0.94% for the Latino/Hispanic subpopulation and -0.86% (p < 0.001) for the overall phase III population. Changes in fasting plasma glucose mirrored those of HbA1c . Weight loss with albiglutide was numerically greater than with OADs and insulin in both populations, but it was smaller than with liraglutide. Within the Latino/Hispanic subpopulation, more injection-site reactions were reported with albiglutide vs all comparators, while gastrointestinal and hypoglycemic adverse events were comparable between the two groups, and the latter was uncommon when used without insulin and/or a sulfonylurea., Conclusions: In the Latino/Hispanic population, albiglutide resulted in effective lowering of glucose and modest weight loss, and it was generally well tolerated.- Published
- 2017
- Full Text
- View/download PDF
43. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
- Author
-
Shaddinger BC, Young MA, Billiard J, Collins DA, Hussaini A, and Nino A
- Subjects
- Adult, Cross-Over Studies, Double-Blind Method, Female, Gallbladder diagnostic imaging, Gallbladder drug effects, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 blood, Glucagon-Like Peptide 1 pharmacokinetics, Glucagon-Like Peptide 1 pharmacology, Humans, Male, Middle Aged, Ultrasonography, Young Adult, Cholecystokinin, Gallbladder Emptying drug effects, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide-1 Receptor agonists
- Abstract
The glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) exenatide and lixisenatide reduce cholecystokinin (CCK)-induced gallbladder emptying in healthy subjects. It is unknown if all GLP-1 RAs share this effect; therefore, the effect of the GLP-1 RA albiglutide on gallbladder function was assessed. In this randomized, double-blind, 2-way crossover study, a single dose of subcutaneous albiglutide 50 mg or placebo was administered to 17 healthy subjects, and CCK-induced gallbladder contractility was measured by ultrasonography. CCK (0.003 μg/kg) was infused intravenously over 50 minutes on study day 4 (3 days after dosing, to coincide with albiglutide's expected time to maximum concentration). Gallbladder volume, ejection fraction, and the main pancreatic and common bile-duct diameters were measured before, during, and following CCK infusion. Gallbladder volume was significantly greater in the albiglutide vs placebo groups before, during, and after CCK infusion, and the mean difference from placebo increased numerically during CCK infusion. The area under the volume-effect curve was significantly greater with albiglutide (P = .029). Starting at the 30-minute CCK infusion time point, the gallbladder ejection fraction was significantly lower with albiglutide than placebo. Changes in pancreatic duct diameter and common bile-duct diameter were not significantly different between albiglutide and placebo. Similar incidences of adverse events were observed between the albiglutide and placebo treatment periods. No new albiglutide safety signals were detected, and no serious adverse events were reported. In conclusion, similar to other GLP-1 RAs, albiglutide decreased CCK-induced gallbladder emptying compared with placebo in healthy individuals. Clinical implications of the gallbladder effects are unclear at this time., (© 2017, The American College of Clinical Pharmacology.)
- Published
- 2017
- Full Text
- View/download PDF
44. The safety of albiglutide for the treatment of type 2 diabetes.
- Author
-
Rendell MS
- Subjects
- Animals, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide-1 Receptor agonists, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents pharmacology, Injections, Weight Loss drug effects, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glycated Hemoglobin metabolism, Hypoglycemic Agents therapeutic use
- Abstract
Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide. Area Covered: The safety of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert Opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events.
- Published
- 2017
- Full Text
- View/download PDF
45. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
- Author
-
Leiter LA, Gross JL, Chow F, Miller D, Johnson S, and Ahrén B
- Subjects
- Diabetes Mellitus, Type 2 blood, Drug Administration Schedule, Drug Monitoring, Drug Resistance, Drug Therapy, Combination adverse effects, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glycated Hemoglobin analysis, Humans, Hypoglycemia chemically induced, Hypoglycemia epidemiology, Hypoglycemia prevention & control, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Incidence, Incretins administration & dosage, Incretins adverse effects, Insulin Glargine administration & dosage, Insulin Glargine adverse effects, Insulin Lispro administration & dosage, Insulin Lispro adverse effects, Insulin Lispro therapeutic use, Meals, Risk, Weight Gain drug effects, Weight Loss drug effects, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide-1 Receptor antagonists & inhibitors, Hyperglycemia prevention & control, Hypoglycemic Agents therapeutic use, Incretins therapeutic use, Insulin Glargine therapeutic use
- Abstract
We have previously reported that once-weekly albiglutide was noninferior to thrice-daily lispro for glycemic lowering, with decreased weight and risk of hypoglycemia, in patients inadequately controlled on basal insulin over 26 weeks. Findings after 52 weeks reveal similar responses to albiglutide as an add-on to insulin glargine., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
- Author
-
Brønden A, Knop FK, and Christensen MB
- Subjects
- Animals, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 pharmacokinetics, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide 1 therapeutic use, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Recombinant Proteins adverse effects, Recombinant Proteins pharmacokinetics, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Treatment Outcome, Glucagon-Like Peptide 1 analogs & derivatives, Hypoglycemic Agents pharmacokinetics, Hypoglycemic Agents pharmacology
- Abstract
Albiglutide is a long-acting, glucagon-like peptide-1 receptor agonist for subcutaneous administration with a recommended dose of 30-50 mg once weekly. The aim of this article is to outline the pharmacokinetic and pharmacodynamic properties of albiglutide including the clinical efficacy and safety data underlying the approval of albiglutide for the treatment of type 2 diabetes mellitus in both Europe and USA. Albiglutide is cleared from the circulation (by a mechanism partially dependent on renal function) with an elimination half-life of 5 days, allowing once-weekly administration. In the clinical trial program called HARMONY, albiglutide demonstrated placebo-corrected reductions in glycosylated hemoglobin of 0.8-1.0%. In addition, reductions in fasting plasma glucose in the range of 1.3-2.4 mmol/L compared with placebo were reported. Albiglutide caused weight reductions at a level comparable to placebo in the HARMONY trials, possibly related to limited central nervous system penetration of the large albiglutide molecule. Albiglutide demonstrated a generally favorable safety profile, although with a signal of an increased risk of pancreatitis. The well-known adverse events related to glucagon-like peptide-1 receptor activation such as nausea, diarrhea, and vomiting were less frequent with albiglutide compared with another glucagon-like peptide-1 receptor agonist, liraglutide, but slightly more frequent following treatment with albiglutide than with placebo or active comparators from other classes of anti-hyperglycemic drugs. The full risk-benefit profile for albiglutide used in treating type 2 diabetes will not be clear until reporting of the long-term cardiovascular outcome trial (HARMONY Outcome) with planned completion in 2019.
- Published
- 2017
- Full Text
- View/download PDF
47. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
- Author
-
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, and Davies MJ
- Subjects
- Blood Glucose drug effects, Diabetes Mellitus, Type 2 blood, Drug Administration Schedule, Exenatide, Female, Glucagon-Like Peptide 1 administration & dosage, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptides administration & dosage, Glucagon-Like Peptides adverse effects, Glycated Hemoglobin drug effects, Humans, Hypoglycemia chemically induced, Hypoglycemic Agents adverse effects, Immunoglobulin Fc Fragments adverse effects, Incretins adverse effects, Liraglutide administration & dosage, Liraglutide adverse effects, Male, Middle Aged, Peptides administration & dosage, Peptides adverse effects, Randomized Controlled Trials as Topic, Recombinant Fusion Proteins adverse effects, Treatment Outcome, Venoms administration & dosage, Venoms adverse effects, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptides analogs & derivatives, Hypoglycemic Agents administration & dosage, Immunoglobulin Fc Fragments administration & dosage, Incretins administration & dosage, Recombinant Fusion Proteins administration & dosage
- Abstract
Aims: To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes., Materials and Methods: We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA. Data on cardiometabolic and safety outcomes were analysed using a mixed-treatment comparison meta-analysis., Results: A total of 34 trials (14 464 participants) met the inclusion criteria; no published data for semaglutide were available. Compared with placebo, all GLP-1RAs reduced glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels (reductions ranged from -0.55% and -0.73 mmol/L, respectively, for lixisenatide to -1.21% and -1.97 mmol/L, respectively, for dulaglutide). There were no differences within short-acting (twice-daily exenatide and lixisenatide) or long-acting (albiglutide, dulaglutide, once-weekly exenatide, liraglutide and taspoglutide) groups. Compared with twice-daily exenatide, dulaglutide treatment was associated with the greatest HbA1c and FPG reduction (0.51% and 1.04 mmol/L, respectively), followed by liraglutide (0.45% and 0.93 mmol/L, respectively) and once-weekly exenatide (0.38% and 0.85 mmol/L, respectively); similar reductions were found when these 3 agents were compared with lixisenatide. Compared with placebo, all GLP-1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure. When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk. Albiglutide had the lowest risk of nausea and diarrhoea and once-weekly exenatide the lowest risk of vomiting., Conclusions: The RCTs in the present analysis show that all GLP-1RAs improve glycaemic control, reduce body weight and increase the risk of adverse gastrointestinal symptoms compared with placebo. Although there were no differences when short-acting agents were compared with each other or when long-acting agents were compared with each other, dulaglutide, liraglutide and once-weekly exenatide were superior to twice-daily exenatide and lixisenatide at lowering HbA1c and FPG levels. There were no differences in hypoglycaemia between these 3 agents, whilst once-weekly exenatide had the lowest risk of vomiting. These results, along with patient's preferences and individualized targets, should be considered when selecting a GLP-1RA., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
48. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
- Author
-
Ahrén B, Carr MC, Murphy K, Perkins C, Rendell M, Mallory J, Wilson T, and Johnson S
- Subjects
- Adult, Aged, Blood Glucose drug effects, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions epidemiology, Female, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemia chemically induced, Hypoglycemia epidemiology, Hypoglycemic Agents adverse effects, Incretins therapeutic use, Injections adverse effects, Insulin therapeutic use, Male, Middle Aged, Sulfonylurea Compounds therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Drug-Related Side Effects and Adverse Reactions etiology, Glucagon-Like Peptide 1 analogs & derivatives, Hypoglycemic Agents therapeutic use
- Abstract
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stimulate the incretin system and lower glycaemic parameters in type 2 diabetes mellitus (T2DM). This analysis of clinical studies of up to 3years evaluated the safety of albiglutide, a GLP-1 RA, in people with T2DM., Methods: Integrated safety analysis included seven phase-3 T2DM studies of albiglutide compared with placebo and/or active comparators (a dipeptidyl peptidase-4 inhibitor, GLP-1 RA, insulin, sulphonylurea, and thiazolidinedione)., Results: Studies of 32months (HARMONY 7), 1year (HARMONY 6), and 3years (HARMONY 1-5), reported similar rates of adverse events (AEs) (84.8%, 82.3%), and serious AEs (13.1%, 12.9%) between albiglutide and all comparators, respectively. AEs that did not differ between the groups included symptomatic or severe hypoglycaemia as well as nausea (12.0%, 11.3%) and vomiting (5.3%, 4.7%) for albiglutide and all comparators, respectively. According to the Medical Dictionary for Regulatory Activities preferred terms, only diarrhoea (13.7%, 9.9%), injection-site reaction (9.0%, 2.0%), and peripheral oedema (4.5%, 6.8%) had at least 2% difference between the albiglutide and all-comparator groups. In a similar integrated analysis, pancreatitis occurred more often with albiglutide (0.3%, 0.1%). Renal and cardiac function did not differ between the two groups., Conclusions: In an integrated analysis of seven phase 3 clinical trials, albiglutide-treated patients experienced frequencies of AEs (including cardiovascular and renal) similar to the all-comparators group treated with other T2DM medications or placebo. Albiglutide treatment was associated with higher rates of diarrhoea and injection-site reactions, but not increased nausea and vomiting, versus all comparators., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
49. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
- Author
-
Okuda I, Wilson TH, Yue L, Nakajima H, Carr MC, Tsuboi M, Nino A, and Seino Y
- Subjects
- Adult, Aged, Blood Glucose analysis, Female, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 therapeutic use, Glycated Hemoglobin analysis, Humans, Hyperglycemia drug therapy, Hypoglycemia chemically induced, Male, Middle Aged, Recombinant Proteins therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide-1 Receptor agonists, Hypoglycemic Agents therapeutic use
- Abstract
Objective: To evaluate the safety and efficacy of once weekly albiglutide added to a single oral antidiabetic drug (OAD) in Japanese patients with inadequately controlled type 2 diabetes mellitus (T2DM)., Research Design and Methods: In this phase 3, 1 year study (NCT01777282), patients (N = 374) received albiglutide 30 mg plus a single OAD (sulfonylurea [n = 120], biguanide [n = 67)], glinide [n = 65], thiazolidinedione [n = 61], or α-glucosidase inhibitor [n = 61]). Albiglutide could be increased to 50 mg after Week 4, based on glycemic criteria. Primary endpoints were the incidence of adverse events (AEs) and hypoglycemia; secondary endpoints were changes from baseline at Week 52 in HbA
1c and fasting plasma glucose (FPG), proportion of patients achieving HbA1c ≤7.0%, and withdrawals due to hyperglycemia., Results: On-therapy AEs occurred in 78.6% of patients and serious AEs in 2.1%. Common AEs were nasopharyngitis (32.6%), constipation (7.2%), and diabetic retinopathy (5.3%). No serious AEs occurred more than once or were reported in >1 patient. Hypoglycemia occurred in 6.4% of patients, mostly in the albiglutide + sulfonylurea (14.2%) and the albiglutide + glinide (6.2%) groups. Albiglutide was uptitrated in 53.2% of patients. Mean baseline HbA1c was 8.1%. Mean decreases from baseline in HbA1c were observed with the addition of albiglutide to thiazolidinediones (-1.42%), α-glucosidase inhibitors (-1.39%), sulfonylureas (-1.04%), glinides (-0.95%), and biguanides (-0.94%). HbA1c of <7% in >50% of patients and mean reductions in FPG were achieved in all groups. Mean changes from baseline in body weight ranged from +0.52 kg (albiglutide + thiazolidinedione) to -0.33 kg (albiglutide + biguanide). Limitations of the study included open label treatment that was not randomized., Conclusions: When combined with a single OAD in Japanese patients with inadequately controlled T2DM, albiglutide led to favorable changes in all glycemic parameters, with minor changes in body weight depending on the background OAD. No new safety concerns were noted.- Published
- 2017
- Full Text
- View/download PDF
50. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
- Author
-
Anyanwagu U, Mamza J, Mehta R, Donnelly R, and Idris I
- Subjects
- Adult, Aged, Biomarkers blood, Blood Glucose drug effects, Blood Glucose metabolism, Cardiovascular Diseases diagnosis, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Cause of Death, Databases, Factual, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 mortality, Drug Therapy, Combination, Female, Glucagon-Like Peptide 1 adverse effects, Glucagon-Like Peptide 1 analogs & derivatives, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents adverse effects, Insulin adverse effects, Kaplan-Meier Estimate, Male, Metformin therapeutic use, Middle Aged, Obesity complications, Obesity mortality, Propensity Score, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Sulfonylurea Compounds therapeutic use, Time Factors, Treatment Outcome, United Kingdom, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide 1 therapeutic use, Hypoglycemic Agents therapeutic use, Insulin therapeutic use
- Abstract
Objectives: To analyse time to cardiovascular events and mortality in patients with type 2 diabetes (T2D) who received treatment intensification with insulin or a glucagon-like peptide-1 (GLP-1ar) analogue following dual therapy failure with metformin (MET) and sulphonylurea (SU)., Methods: A retrospective cohort study was conducted in 2003 patients who were newly treated with a GLP-1ar or insulin following dual therapy (MET+SU) failure between 2006 and 2014. Data were sourced from The Health Improvement Network database. Risks of major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, non-fatal stroke and all-cause mortality) were compared between MET+SU+insulin (N=1584) versus MET+SU+GLP-1ar (N=419). Follow-up was for 5 years (6614 person-years). Propensity score matching analysis and Cox proportional hazard models were employed., Results: Mean age was 52.8±14.1 years. Overall, the number of MACE was 231 vs 11 for patients who added insulin versus GLP-1ar, respectively (44.5 vs 7.7 per 1000-person-years adjusted HR (aHR): 0.27; 95% CI 0.14 to 0.53; p<0.0001). Insulin was associated with significant increase in weight compared with GLP-1ar (1.78 vs -3.93 kg; p<0.0001) but haemoglobin A1c reduction was similar between both treatment groups (-1.29 vs -0.98; p=0.156). In a subgroup analysis of obese patients (body mass index >30 kg/m(2)) there were 84 vs 11 composite outcomes (38.6 vs 8.1 per 1000 person-years; aHR: 0.31; 95% CI 0.16 to 0.61; p=0.001) in the insulin and GLP-1ar groups, respectively., Conclusions: In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.